Cyclacel's Seliciclib Found Effective Against Lung Cancer Cell Lines Including K-RAS Mutations
January 07, 2010 12:08 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 7, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced the publication of two peer-reviewed journal articles featuring the...
Cyclacel Pharmaceuticals to Present at OneMedForum 2010
January 06, 2010 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 6, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that Spiro Rombotis, President and Chief Executive Officer, will...
Cyclacel Announces Publication of Peer-Reviewed Journal Article Describing the Mechanism of Action of Seliciclib
December 30, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 30, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced the publication of an article that reviews and discusses the...
Cyclacel Receives NASDAQ Notice of Non-Compliance
December 15, 2009 16:05 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 15, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced that, on December 9, 2009, the...
Cyclacel Provides Update on Meeting With FDA to Discuss Pivotal Study Design for Sapacitabine
December 15, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 15, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today that the Company recently held a...
Cyclacel Reports Phase 2 Sapacitabine Data in Acute Myeloid Leukemia and Myelodysplastic Syndromes at 2009 ASH Annual Meeting
December 05, 2009 10:00 ET
|
Cyclacel
Planning Underway for a Pivotal Trial to Start in 2010
Conference Call Scheduled for Monday December 7th at 9:30 AM
Eastern
BERKELEY HEIGHTS, N.J., Dec....
Cyclacel to Host Conference Call on Monday, December 7 to Discuss New Phase 2 Sapacitabine Data to be Presented at ASH
December 01, 2009 12:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 1, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") will host a conference call on Monday, December 7...
Sapacitabine Phase 1 Data Published in Acute Leukemia and Myelodysplastic Syndromes
November 30, 2009 09:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 30, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced publication in the Journal of Clinical...
Cyclacel Pharmaceuticals to Present Sapacitabine Phase 2 AML & MDS Data at the Upcoming American Society of Hematology Meeting
November 17, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today that updated Phase 2 clinical trial...
Cyclacel Pharmaceuticals Announces Third Quarter 2009 Financial Results
November 03, 2009 16:01 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 3, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today financial and operating results for...